Champions Oncology, Inc. (CSBR) financial statements (2020 and earlier)

Company profile

Business Address 855 N. WOLFE STREET
BALTIMORE, MD 21205
State of Incorp. DE
Fiscal Year End April 30
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

1/31/2020
TTM
4/30/2019
4/30/2018
4/30/2017
4/30/2016
4/30/2015
4/30/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3313396
Cash and cash equivalents3313396
Receivables4442122
Other undisclosed current assets00000(0)(1)
Total current assets:88564118
Noncurrent Assets
Operating lease, right-of-use asset3
Property, plant and equipment3321100
Intangible assets, net (including goodwill)1111111
Goodwill1111111
Restricted cash and investments  00000
Other noncurrent assets0000   
Total noncurrent assets:7332111
TOTAL ASSETS:1511886129
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3433222
Accounts payable2322211
Accrued liabilities1111001
Deferred revenue5
Debt10     
Deferred revenue and credits55322
Other undisclosed current liabilities 4     
Total current liabilities:8877544
Noncurrent Liabilities
Long-term debt and lease obligation3 000  
Capital lease obligations 000  
Operating lease, liability3
Liabilities, other than long-term debt, including:0000002
Deferred rent credit 1
Other liabilities001000 
Derivative instruments and hedges, liabilities      2
Other undisclosed liabilities, other than long-term debt (1)(0)(0)(0)(0) 
Other undisclosed noncurrent liabilities 10000 
Total noncurrent liabilities:3110002
Total liabilities:12988646
Stockholders' equity
Stockholders' equity attributable to parent3200083
Common stock0000000
Treasury stock, value  (1)(1)(1)(1)(1)
Additional paid in capital74737271646143
Accumulated deficit(71)(71)(71)(69)(62)(52)(39)
Total stockholders' equity:3200083
TOTAL LIABILITIES AND EQUITY:1511886129

Income statement (P&L) ($ in millions)

1/31/2020
TTM
4/30/2019
4/30/2018
4/30/2017
4/30/2016
4/30/2015
4/30/2014
Revenues3127201511912
Revenue, net201511912
Cost of revenue
(Cost of Goods and Services Sold)
(12)      
Other undisclosed gross profit10      
Gross profit:2927201511912
Operating expenses(31)(27)(22)(22)(21)(22)(18)
Other undisclosed operating income2      
Operating income (loss):(0)0(1)(7)(10)(13)(6)
Nonoperating income (expense)(0)(0)(0)(0)(0)0(1)
Investment income, nonoperating     1(1)
Other nonoperating expense(0)(0)(0)(0)(0)(0)(0)
Income (loss) from continuing operations before income taxes:(0)0(1)(7)(10)(13)(7)
Income tax expense(0)(0)(0)(0)(0)(0)(0)
Other undisclosed loss from continuing operations(0)      
Net income (loss):(0)0(1)(7)(10)(13)(7)
Other undisclosed net income attributable to parent   00  
Net income (loss) available to common stockholders, basic:(0)0(1)(7)(10)(13)(7)
Other undisclosed net loss available to common stockholders, diluted     (1) 
Net income (loss) available to common stockholders, diluted:(0)0(1)(7)(10)(14)(7)

Comprehensive Income ($ in millions)

1/31/2020
TTM
4/30/2019
4/30/2018
4/30/2017
4/30/2016
4/30/2015
4/30/2014
Net income (loss):(0)0(1)(7)(10)(13)(7)
Comprehensive income (loss):(0)0(1)(7)(10)(13)(7)
Other undisclosed comprehensive income, net of tax, attributable to parent      0
Comprehensive income (loss), net of tax, attributable to parent:(0)0(1)(7)(10)(13)(7)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: